News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
Publication
Dermatology Times
More
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
    • Biologic Treatments for Moderate to Severe Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
    • Emerging Therapies Plaque Psoriasis
    • Treatments for Plaque Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Skin Cancer (Nonmelanoma)
  • Vitiligo
  • Wound Care
Advertisement

Sumrah Jilani

Advertisement

Articles by Sumrah Jilani

Vitiligo, Melasma, PIH, and Albinism: Clinical Update and Emerging Therapies

ByRebecca Urbonas,Sumrah Jilani,Bernard A. Cohen, MD
February 10th 2025

Review emerging therapies for vitiligo, melasma, PIH, and albinism, including topical, systemic, light-based, and laser treatments.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Dermatology Times

    1

    Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

    2

    Reviewing Type 2 Inflammation Through a Different Lens

    3

    Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott

    4

    How Clinicians are Navigating JAK Inhibitors and Patient Expectations in Alopecia Areata

    5

    Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic

    • About
    • Advertise
    • Contact Us
    • Job Board
    • Do Not Sell My Information
    • Terms and Conditions
    • Privacy Policy
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us